Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.

Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L.

J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691.

2.

Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.

Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR.

Pharmacol Biochem Behav. 2012 Jan;100(3):530-7. doi: 10.1016/j.pbb.2011.10.019. Epub 2011 Oct 25.

PMID:
22056608
3.

Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.

Todtenkopf MS, O'Neill KS, Kriksciukaite K, Turncliff RZ, Dean RL, Ostrovsky-Day I, Deaver DR.

Addict Biol. 2009 Sep;14(4):408-18. doi: 10.1111/j.1369-1600.2009.00161.x. Epub 2009 Jun 1.

PMID:
19489752
4.

Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.

Dunbar JL, Turncliff RZ, Hayes SC, Farrell CB.

J Stud Alcohol Drugs. 2007 Nov;68(6):862-70.

PMID:
17960304
5.

Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.

Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL.

J Pharmacol Exp Ther. 2006 Aug;318(2):881-9. Epub 2006 May 11.

PMID:
16690724
6.

Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes.

Turncliff RZ, Tian X, Brouwer KL.

Biochem Pharmacol. 2006 May 14;71(10):1520-9. Epub 2006 Mar 15.

PMID:
16542640
7.

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.

Alcohol Clin Exp Res. 2006 Mar;30(3):480-90.

PMID:
16499489
8.

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.

Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC.

J Clin Pharmacol. 2005 Nov;45(11):1259-67.

PMID:
16239359
9.
10.
11.

Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver.

Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL.

J Pharmacol Exp Ther. 2003 Feb;304(2):801-9.

PMID:
12538836
12.

P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes.

Annaert PP, Turncliff RZ, Booth CL, Thakker DR, Brouwer KL.

Drug Metab Dispos. 2001 Oct;29(10):1277-83.

PMID:
11560870
13.

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.

Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RZ.

Br J Clin Pharmacol. 2000;49 Suppl 1:27S-33S.

14.

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.

Everson G, Lasseter KC, Anderson KE, Bauer LA, Carithens RL Jr, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ.

Br J Clin Pharmacol. 2000;49 Suppl 1:21S-26S.

15.

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.

Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, Hansen RA.

Br J Clin Pharmacol. 2000;49 Suppl 1:15S-20S.

Supplemental Content

Loading ...
Support Center